NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
ARS Pharmaceuticals, Inc. SPRY
6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$84.3M
▼ 5.5% vs FY2024
EPS · FY25
$-1.74
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-92.3%
Net margin · FY25
-203.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 84.3M
Revenue, FY2025 · full 6-year series below
Revenue
Net income
The company lost 203 cents on every revenue dollar this year.
Per share
USD -1.74
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-92.3%
Return on equity, FY2025
ROE
Operating margin-212.9%
Net margin-203.3%
Return on assets-50.5%
Each USD of equity lost 92 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+300.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.10B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 327.7M
total assets, end of FY2025
Total assetsUSD 327.7M
EquityUSD 114.3M
CashUSD 41.3M
Gross debtUSD 96.4M
Net debtUSD 55.1M
Current ratio7.28×
Net debt stands at 48% of equity.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
0.1
0.1
0.0
0.0
0.0
·
Operating income $B
−0.2
−0.0
−0.1
−0.0
−0.0
−0.0
EBITDA $B
·
−0.0
−0.1
−0.0
−0.0
−0.0
Income tax $B
−0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.2
0.0
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−1.74
0.08
−0.57
−0.87
−0.70
−11.33
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
−92.3
3.3
−21.6
−28.7
·
·
Shares out B
0.10
0.10
0.10
0.09
0.03
0.03
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
18 of 18
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed